

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-5 (canceled)

6. (New) A spray containing ubiquinone Q-10 in an aqueous colloidal dispersion.
7. (New) The spray according to claim 6, characterized by being an oral or nasal spray.
8. (New) A method of using the spray according to claim 6 comprising administering a dose of the spray to a person in need thereof, by spraying orally or nasally, for the treatment of pain conditions from neural disorders, wherein the ubiquinone Q-10 is present in amount of 20-1000 mg/dose.
9. (New) A method of using the spray according to claim 6 comprising administering the spray to a person in need thereof, by spraying orally or nasally, for the treatment of migraine or neuropathy.
10. (New) A method of using the spray according to claim 6 comprising administering the spray to a person in need thereof, by spraying orally or nasally, for the treatment of depression, psychosis, or lack of concentration.

11. (New) A method of using the spray according to claim 6 comprising administering a dose of the spray to a person in need thereof, by spraying orally or nasally, for the treatment of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, or cerebral palsy, wherein ubiquinone Q-10 is present at an amount of 20-1000 mg/dose.